Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Product Type
Item No. 37020

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.
DOWNLOAD NOWRespiratory syncytial virus (RSV) fusion (F) protein is a surface glycoprotein encoded by the F gene in RSV RNA.1 It is synthesized as an inactive precursor protein, F0, that undergoes proteolytic cleavage to release the F1 and F2 subunits, which are joined together by two disulfide bonds.2 Mature RSV F protein is composed of an N-terminal fusion peptide (FP), two heptad repeats (HRs), a transmembrane domain, and a cytoplasmic tail and assembles into homotrimers on the virus surface.1 Upon insertion of the FP in the target cell membrane, the HRs form a six-helical bundle (6-HB) that enables RSV to fuse with the target cell. RSV F protein is highly conserved between RSV subtypes A and B with approximately 90% amino acid identities.3 RSV is the most common causative agent of pediatric lower respiratory tract infections.4 Cayman's RSV F Protein Extracellular Domain (Strain RSS-2) (recombinant) protein consists of 519 amino acids, has a calculated molecular weight of 57.8 kDa, and a predicted N-terminus of Phe22 after signal peptide cleavage. By SDS-PAGE, under reducing conditions, the apparent molecular mass of the F0 and F1 proteins is approximately 63 and 44-53 kDa, respectively, due to glycosylation.
WARNING This product is not for human or veterinary use.
1. Challenges and opportunities for respiratory syncytial virus vaccines. Curr. Top. Microbiol. Immunol. 372, 391-404 (2013).
2. Contribution of cysteine residues in the extracellular domain of the F protein of human respiratory syncytial virus to its function. Virol. J. 3, 34 (2006).
3. Analysis of respiratory syncytial virus fusion protein from clinical isolates of Korean children in palivizumab era, 2009-
4. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and meta-